TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29569351

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (3 times a week for 4 weeks)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (bed rest)
Number of subjects: 111
Study: 28644212

Group type: EXPERIMENTAL
Intervention: Worsened AVC group
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Stable AVC group
Number of subjects: 2964
Study: 26139208

Group type: EXPERIMENTAL
Intervention: Kalon HSV-2 ELISA
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Disclosure of positive HSV-2 results
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Self-reported virginity
Number of subjects: 837
Study: 24176188

Group type: EXPERIMENTAL
Intervention: Variable PSV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-variable PSV
Number of subjects: 0
Study: 21393644

Group type: EXPERIMENTAL
Intervention: Manual therapy combined with standard therapy (TENS, ultrasound therapy, kinesiotherapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy (TENS, ultrasound therapy, kinesiotherapy)
Number of subjects: 30
Study: 18312757

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 8290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8290
Study: 16649856

Group type: EXPERIMENTAL
Intervention: High power priming
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low power priming
Number of subjects: 6
Study: 12846598

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) - passive maxillary plates during the first year of life
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (IO-) - did not wear passive maxillary plates
Number of subjects: 0
Study: 10803671

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/mL
Number of subjects: 132

Group type: COMPARATOR
Intervention: Iohexol 300 mg I/mL
Number of subjects: 132
Study: 9032862

Group type: EXPERIMENTAL
Intervention: Gamma Knife treatment
Number of subjects: 36
Study: 1909637

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg b.i.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg b.i.d. plus 4 g cholestyramine o.d.
Number of subjects: 18
Study: 6614958

Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream applied daily to vitiliginous lesions under occlusive dressings
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream
Number of subjects: 28
Study: 31774833

Group type: EXPERIMENTAL
Intervention: Topper Training
Number of subjects: 132

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 132
Study: 29026936

Group type: EXPERIMENTAL
Intervention: Graded full-thickness blepharotomy (G1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transconjunctival Müller muscle recession and graded disinsertion of the levator palpebrae superioris muscle (G2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both groups (G1 and G2)
Number of subjects: 27
Study: 26416521

Group type: EXPERIMENTAL
Intervention: long/GH
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: short/GH
Number of subjects: 287
Study: 24427348

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study: 22209479

Group type: EXPERIMENTAL
Intervention: Intra-hepatic fat
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Total thoracic fat
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Epicardial fat
Number of subjects: 650
Study: 21108491

Group type: EXPERIMENTAL
Intervention: Silver ring splint (SRS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prefabricated thermoplastic splint (PTS)
Number of subjects: 50
Study: 17609842

Group type: EXPERIMENTAL
Intervention: Interferential currents (IFT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Horizontal therapy (HT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sham horizontal therapy (Control)
Number of subjects: 115
Study: 16271479

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Late open lung concept (LOL)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Early open lung concept (EOL)
Number of subjects: 62
Study: 12392122

Group type: EXPERIMENTAL
Intervention: Information intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information plus evidence intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (neither intervention)
Number of subjects: 0
Study: 9894691

Group type: EXPERIMENTAL
Intervention: Dynamic transformation in perspective of pairs of coplanar ellipses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static upright view reproduction task
Number of subjects: 0
Study: 7567311

Group type: EXPERIMENTAL
Intervention: Ceftibuten 9 mg/kg once daily (max 400 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cefaclor 40 mg/kg/day in three divided doses (max 1 g/day)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 154
Study: 2095647

Group type: EXPERIMENTAL
Intervention: Immunoglobulin preparation (Pentaglobin) administered intravenously
Number of subjects: 35
Study: 7272608

Group type: EXPERIMENTAL
Intervention: Guided mourning treatment (facing cues concerning bereavement)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control treatment (avoiding cues concerning bereavement)
Number of subjects: 12
Study: 31246103

Group type: EXPERIMENTAL
Intervention: Psychiatric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychiatric patients with higher internalized stigma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychiatric patients who avoided disclosure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Married and older psychiatric patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical patient controls
Number of subjects: 0
Study: 30026002

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 26471889

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0·015% gel
Number of subjects: 450

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 450
Study: 24501015

Group type: EXPERIMENTAL
Intervention: telehealth problem-solving therapy (tele-PST via Skype video call)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: in-person problem-solving therapy (PST)
Number of subjects: 158
Study: 22819575

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lignocaine (20 ml of 0.5% lignocaine)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (20 ml of isotonic saline)
Number of subjects: 196
Study: 20045576

Group type: EXPERIMENTAL
Intervention: IV prochlorperazine with 12.5 mg diphenhydramine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan (6 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IV prochlorperazine with diphenhydramine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 68
Study: 17336795

Group type: EXPERIMENTAL
Intervention: Distress manipulation (anticipation of a public speaking task)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 86
Study: 15966756

Group type: EXPERIMENTAL
Intervention: CYP3A induction (rifampicin)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CYP3A inhibition (troleandomycin)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no CYP3A induction or inhibition)
Number of subjects: 13
Study: 12464140

Group type: EXPERIMENTAL
Intervention: G. biloba extract (Gibidyl Forte(R))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9493514

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN-alpha2a)
Number of subjects: 26
Study: 7657737

Group type: EXPERIMENTAL
Intervention: Zoladex depot (single injection)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Suprefact (multiple daily injections)
Number of subjects: 142
Study: 2501372

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT)
Number of subjects: 11
Study: 21345

Group type: EXPERIMENTAL
Intervention: etilefrin (Effortil Depot Perlongets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30378756

Group type: EXPERIMENTAL
Intervention: Visual feedback of the neck using mirrors (experimental group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No visual feedback (control group)
Number of subjects: 42
Study: 28600818

Group type: EXPERIMENTAL
Intervention: Ustekinumab every 12 weeks (q12 wk) maintenance (n=76)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ustekinumab every 12-24 weeks (q12-24 wk) maintenance (n=302)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Ustekinumab every 12 weeks (q12 wk) maintenance
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ustekinumab every 12-24 weeks (q12-24 wk) maintenance
Number of subjects: 378
Study: 25162967

Group type: COMPARATOR
Intervention: Low-dose metformin (250 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Middle-dose metformin (500 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-dose metformin (1500 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (untreated with metformin)
Number of subjects: 120
Study: 23486306

Group type: EXPERIMENTAL
Intervention: Standard Su‐Per treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Su‐Per treatment without higher stimulus at interspinous line
Number of subjects: 40
Study: 21112173

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: DVD intervention
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 926
Study: 19513760

Group type: EXPERIMENTAL
Intervention: Needle acupuncture (3 sessions)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Metamizole (3x1000 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 66
Study: 16847010

Group type: EXPERIMENTAL
Intervention: Residual thrombus in a patent epicardial artery
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: Thrombus presence
Number of subjects: 2684

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2684
Study: 15320660

Group type: EXPERIMENTAL
Intervention: Squat Jump (SJ)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All jumping tests
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Principal Component Analysis of jumping tests
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CMJ test
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Other jumping tests
Number of subjects: 93
Study: 11752508

Group type: EXPERIMENTAL
Intervention: Corticosteroids (Cs) treatment
Number of subjects: 410

Group type: COMPARATOR
Intervention: No corticosteroids (Cs) treatment
Number of subjects: 410
Study: 10876967

Group type: EXPERIMENTAL
Intervention: Oral natural alpha‐Interferon (OROFERONE‐IFI) at 150U tid for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8880052

Group type: EXPERIMENTAL
Intervention: Deflazacort (12 mg, 30 mg, 60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone (8 mg, 20 mg, 40 mg)
Number of subjects: 0
Study: 2068049

Group type: EXPERIMENTAL
Intervention: L-acetyl carnitine (1.5 g, intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium acetate (placebo)
Number of subjects: 20
Study: 6350033

Group type: EXPERIMENTAL
Intervention: Acetylcysteine 200 mg b.i.d. for 6 months
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo b.i.d. for 6 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 31302601

Group type: EXPERIMENTAL
Intervention: PROMPT training package (Second edition)
Number of subjects: 87204
Study: 31149001

Group type: EXPERIMENTAL
Intervention: LMA airway cuff pressures adjusted to 30 to 32cm of H2O
Number of subjects: 80

Group type: COMPARATOR
Intervention: Only monitoring of LMA cuff pressures
Number of subjects: 80
Study: 30219052

Group type: EXPERIMENTAL
Intervention: exercise plus ADCR
Number of subjects: 45
Study: 26431466

Group type: EXPERIMENTAL
Intervention: IDflu9μg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: IDflu15μg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Agrippal
Number of subjects: 86
Study: 24474302

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg days 1 and 15, rifampicin 600 mg days 8-14
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg day 1, erlotinib 450 mg day 15, rifampicin 600 mg days 8-18
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (erlotinib 150 mg days 1 and 15)
Number of subjects: 0
Study: 21946707

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Weight loss (overall)
Number of subjects: 99
Study: 19305994

Group type: EXPERIMENTAL
Intervention: MRI showing treatable pathology
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Arthroscopy in group 1 patients
Number of subjects: 274

Group type: COMPARATOR
Intervention: Arthroscopy in group 2 patients
Number of subjects: 274
Study: 17242088

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.4 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no remifentanil)
Number of subjects: 72
Study: 15919304

Group type: EXPERIMENTAL
Intervention: Total leukocyte filtration
Number of subjects: 300
Study: 12356782

Group type: EXPERIMENTAL
Intervention: Glucose plus 0.08 g/kg body weight of Z‐trim
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose plus 0.17 g/kg body weight of Z‐trim
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose plus 0.33 g/kg body weight of Z‐trim
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose alone (1 g/kg body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose plus fiber (any level)
Number of subjects: 24
Study: 9683311

Group type: EXPERIMENTAL
Intervention: Amoxicillin and omeprazole
Number of subjects: 3411

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with vitamin C, vitamin E, and selenium
Number of subjects: 3411

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with steam‐distilled garlic oil and Kyolic aged garlic extract
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3411
Study: 8086015

Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty
Number of subjects: 44

Group type: COMPARATOR
Intervention: Open acromioplasty
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 2676027

Group type: EXPERIMENTAL
Intervention: Relaxation response (educational information and practice before and after surgery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (only educational information)
Number of subjects: 27
Study: 30851097

Group type: EXPERIMENTAL
Intervention: EOCS
Number of subjects: 318

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 318
Study: 28158703

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC) for 20 minutes
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 75
Study: 25927936

Group type: EXPERIMENTAL
Intervention: Late initiation of parenteral nutrition (PN) beyond PICU-day 7 when enteral nutrition (EN) fails
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Early initiation of parenteral nutrition (PN) within the first days to reach caloric target (control group)
Number of subjects: 1440
Study: 24432675

Group type: EXPERIMENTAL
Intervention: Ruji Recipe (RR) therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 22151676

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (50:50) self-administered until pain relief achieved (max 15 min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl (2 µg/kg) as a single dose
Number of subjects: 100
Study: 19554988

Group type: EXPERIMENTAL
Intervention: Interactive group discussion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study: 16382319

Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU plus calcium 1 g daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 40
Study: 15248630

Group type: EXPERIMENTAL
Intervention: Bilateral paravertebral blockade combined with general anaesthesia (active)
Number of subjects: 60
Study: 10886045

Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (RCM)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: bismuth subcitrate 240 mg b.d. + amoxycillin 1000 mg b.d. + metronidazole 500 mg b.d. (BAM)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg o.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (OCM)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overall resistant strains
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Sensitivity to both antibiotics
Number of subjects: 210
Study: 9076205

Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas
Number of subjects: 514

Group type: COMPARATOR
Intervention: Silicone oil
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Gas-treated eyes
Number of subjects: 514

Group type: COMPARATOR
Intervention: Silicone oil-treated eyes
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Oil-removed eyes
Number of subjects: 514
Study: 8322031

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxindanac
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 32
Study: 2950915

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream and shampoo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29074043

Group type: EXPERIMENTAL
Intervention: Change in lymphocyte to neutrophil ratio (ΔLNR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LNR at baseline and at 3, 6, and 12 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Area under the curve of ΔLNR for acute rejection
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Best cutoff value of ΔLNR
Number of subjects: 74
Study: 27438344

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 1000
Study: 25555593

Group type: EXPERIMENTAL
Intervention: Wufuxinnaoqing Soft Capsule (WSC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (WSC mimetic)
Number of subjects: 240
Study: 23988379

Group type: EXPERIMENTAL
Intervention: Intravenous idursulfase 0.5 mg/kg weekly for two years
Number of subjects: 63
Study: 20227099

Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition (immune-enhancing diets enriched with arginine, omega-3 fatty acids, and RNA for 5 days before and after surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative enteral infusion of the same enriched formula
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 30
Study: 18098274

Group type: EXPERIMENTAL
Intervention: BoNT‐A
Number of subjects: 111

Group type: COMPARATOR
Intervention: BoNT‐B
Number of subjects: 111
Study: 16049264

Group type: EXPERIMENTAL
Intervention: Parent-centered, ecodevelopmental HIV preventive intervention
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Parent-facilitator relationship quality
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group cohesion
Number of subjects: 91
Study: 13677272

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (0.1 R)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (0.2 R)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0.125% bupivacaine (0.125 B)
Number of subjects: 56
Study: 10372954

Group type: EXPERIMENTAL
Intervention: High-dose physostigmine infusion (1-1.5 mg over 45-60 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Chronic physostigmine administration (2-12 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Physostigmine (cognition-enhancing doses)
Number of subjects: 9
Study: 9304934

Group type: COMPARATOR
Intervention: Surgical instruments covered with dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical instruments exposed to air
Number of subjects: 0
Study: 2053197

Group type: EXPERIMENTAL
Intervention: 50 mg 17 beta‐oestradiol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6354030

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study: 29679919

Group type: EXPERIMENTAL
Intervention: Growth hormone administration
Number of subjects: 50
Study: 27333588

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month (PP3M) formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month (PP1M) formulation
Number of subjects: 0
Study: 25027585

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg daily for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg daily for 12 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 26
Study: 22808721

Group type: EXPERIMENTAL
Intervention: 100% feedback frequency
Number of subjects: 19

Group type: COMPARATOR
Intervention: 62% faded feedback frequency
Number of subjects: 19
Study: 20831683

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2
Number of subjects: 22